company background image
3205

Sagittarius Life Science TPEX:3205 Stock Report

Last Price

NT$46.40

Market Cap

NT$1.5b

7D

-12.3%

1Y

81.3%

Updated

30 Sep, 2022

Data

Company Financials
3205 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

3205 Stock Overview

Sagittarius Life Science Corp researches and develops plant drugs in Taiwan.

Sagittarius Life Science Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sagittarius Life Science
Historical stock prices
Current Share PriceNT$46.40
52 Week HighNT$79.20
52 Week LowNT$20.65
Beta0.30
1 Month Change-39.58%
3 Month Change26.43%
1 Year Change81.25%
3 Year Change-11.28%
5 Year Change-39.03%
Change since IPO-61.29%

Recent News & Updates

Shareholder Returns

3205TW Personal ProductsTW Market
7D-12.3%-5.8%-5.5%
1Y81.3%-6.2%-19.3%

Return vs Industry: 3205 exceeded the TW Personal Products industry which returned -6.2% over the past year.

Return vs Market: 3205 exceeded the TW Market which returned -19.3% over the past year.

Price Volatility

Is 3205's price volatile compared to industry and market?
3205 volatility
3205 Average Weekly Movement11.9%
Personal Products Industry Average Movement5.9%
Market Average Movement5.2%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 3205 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: 3205's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
1998n/an/ahttps://www.naturalbiokey.com

Sagittarius Life Science Corp researches and develops plant drugs in Taiwan. The company engages in the development of Chinese herbal medicine technology platform for the treatment of various diseases. It also offers nutritional supplements, health foods, and health related products.

Sagittarius Life Science Fundamentals Summary

How do Sagittarius Life Science's earnings and revenue compare to its market cap?
3205 fundamental statistics
Market CapNT$1.51b
Earnings (TTM)-NT$91.10m
Revenue (TTM)NT$555.27m

2.7x

P/S Ratio

-16.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
3205 income statement (TTM)
RevenueNT$555.27m
Cost of RevenueNT$469.13m
Gross ProfitNT$86.14m
Other ExpensesNT$177.24m
Earnings-NT$91.10m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.80
Gross Margin15.51%
Net Profit Margin-16.41%
Debt/Equity Ratio0%

How did 3205 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 3205 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3205?

Other financial metrics that can be useful for relative valuation.

3205 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.5x
Enterprise Value/EBITDA-15x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 3205's PS Ratio compare to its peers?

3205 PS Ratio vs Peers
The above table shows the PS ratio for 3205 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.1x
6703 Shiny Brands Group
1.4xn/aNT$2.0b
1731 Maywufa
1.8xn/aNT$2.4b
4732 NatureWise Biotech & Medicals
5.2xn/aNT$1.5b
1796 GeneFerm Biotechnology
3.9xn/aNT$2.3b
3205 Sagittarius Life Science
2.7xn/aNT$1.5b

Price-To-Sales vs Peers: 3205 is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (3.1x).


Price to Earnings Ratio vs Industry

How does 3205's PE Ratio compare vs other companies in the TW Personal Products Industry?

Price-To-Sales vs Industry: 3205 is expensive based on its Price-To-Sales Ratio (2.7x) compared to the TW Personal Products industry average (2.7x)


Price to Sales Ratio vs Fair Ratio

What is 3205's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3205 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 3205's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 3205 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 3205's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 3205's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Sagittarius Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.8%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sagittarius Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

Past Performance

How has Sagittarius Life Science performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-2.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 3205 is currently unprofitable.

Growing Profit Margin: 3205 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3205 is unprofitable, and losses have increased over the past 5 years at a rate of 2% per year.

Accelerating Growth: Unable to compare 3205's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3205 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (-11.6%).


Return on Equity

High ROE: 3205 has a negative Return on Equity (-18.95%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Sagittarius Life Science's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 3205's short term assets (NT$349.6M) exceed its short term liabilities (NT$97.0M).

Long Term Liabilities: 3205's short term assets (NT$349.6M) exceed its long term liabilities (NT$32.8M).


Debt to Equity History and Analysis

Debt Level: 3205 is debt free.

Reducing Debt: 3205 had no debt 5 years ago.

Debt Coverage: 3205 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 3205 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Sagittarius Life Science current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Sagittarius Life Science Dividend Yield vs Market
How does Sagittarius Life Science dividend yield compare to the market?
SegmentDividend Yield
Company (Sagittarius Life Science)0%
Market Bottom 25% (TW)2.6%
Market Top 25% (TW)7.0%
Industry Average (Personal Products)3.8%
Analyst forecast in 3 Years (Sagittarius Life Science)n/a

Notable Dividend: Unable to evaluate 3205's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 3205's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3205's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3205's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: 3205 is not paying a notable dividend for the TW market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 3205 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Sagittarius Life Science has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 3205?
Owner TypeNumber of SharesOwnership Percentage

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Company Information

Sagittarius Life Science Corp's employee growth, exchange listings and data sources


Key Information

  • Name: Sagittarius Life Science Corp
  • Ticker: 3205
  • Exchange: TPEX
  • Founded: 1998
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: NT$1.510b
  • Shares outstanding: 32.55m
  • Website: https://www.naturalbiokey.com

Number of Employees


Location

  • Sagittarius Life Science Corp
  • No.3, Yuanqu Street
  • 10F-6
  • Taipei
  • 115
  • Taiwan


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
3205TPEX (Taipei Exchange)YesCommon StockTWTWDMay 2004

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/30 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.